Growth and Proliferation of Renal Cell Carcinoma Cells Is Blocked by Low Curcumin Concentrations Combined with Visible Light Irradiation.
cell cycling
curcumin
renal cell cancer
tumor growth
tumor proliferation
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
22 Mar 2019
22 Mar 2019
Historique:
received:
05
02
2019
revised:
13
03
2019
accepted:
21
03
2019
entrez:
27
3
2019
pubmed:
27
3
2019
medline:
18
7
2019
Statut:
epublish
Résumé
The anti-cancer properties of curcumin in vitro have been documented. However, its clinical use is limited due to rapid metabolization. Since irradiation of curcumin has been found to increase its anti-cancer effect on several tumor types, this investigation was designed to determine whether irradiation with visible light may enhance the anti-tumor effects of low-dosed curcumin on renal cell carcinoma (RCC) cell growth and proliferation. A498, Caki1, and KTCTL-26 cells were incubated with curcumin (0.1⁻0.4 µg/mL) and irradiated with 1.65 J/cm² visible light for 5 min. Controls were exposed to curcumin or light alone or remained untreated. Curcumin plus light, but not curcumin or light exposure alone altered growth, proliferation, and apoptosis of all three RCC tumor cell lines. Cells were arrested in the G0/G1 phase of the cell cycle. Phosphorylated (p) CDK1 and pCDK2, along with their counter-receptors Cyclin B and A decreased, whereas p27 increased. Akt-mTOR-signaling was suppressed, the pro-apoptotic protein Bcl-2 became elevated, and the anti-apoptotic protein Bax diminished. H3 acetylation was elevated when cells were treated with curcumin plus light, pointing to an epigenetic mechanism. The present findings substantiate the potential of combining low curcumin concentrations and light as a new therapeutic concept to increase the efficacy of curcumin in RCC.
Identifiants
pubmed: 30909499
pii: ijms20061464
doi: 10.3390/ijms20061464
pmc: PMC6471746
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Curcumin
IT942ZTH98
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Brigitta & Norbert Muth Stiftung, Wiesbaden, Germany; the Alfons & Gertrud Kassel-Stiftung, Frankfurt, Germany; Friedrich-Spicker-Stiftung, Wuppertal, Germany.
ID : N/A
Organisme : Alfons und Gertrud Kassel-Stiftung
ID : N/A
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Photochem Photobiol Sci. 2005 Jul;4(7):523-30
pubmed: 15986060
Future Oncol. 2005 Jun;1(3):405-14
pubmed: 16556014
J Environ Pathol Toxicol Oncol. 2006;25(1-2):205-15
pubmed: 16566718
J Invest Dermatol. 2007 Aug;127(8):1992-2000
pubmed: 17410200
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Photochem Photobiol. 2008 Jan-Feb;84(1):228-35
pubmed: 18173725
Cancer Treat Rev. 2008 May;34(3):193-205
pubmed: 18313224
Cell Div. 2008 Oct 03;3:14
pubmed: 18834508
Int J Cancer. 2009 Mar 15;124(6):1422-8
pubmed: 19035461
Br J Cancer. 2009 May 5;100(9):1425-33
pubmed: 19401701
Mol Cell Biochem. 2010 Mar;336(1-2):85-95
pubmed: 19826768
Int J Cancer. 2010 Apr 1;126(7):1771-5
pubmed: 19830693
Int J Oncol. 2011 Aug;39(2):319-28
pubmed: 21617861
Integr Cancer Ther. 2012 Sep;11(3):187-203
pubmed: 22019489
J Urol. 2012 Jan;187(1):289-95
pubmed: 22099991
J Urol. 2012 Dec;188(6):2095-100
pubmed: 23083849
J Biomed Opt. 2012 Sep;17(9):98002-1
pubmed: 23085928
Eur Urol. 2014 Jun;65(6):1086-92
pubmed: 23916693
PLoS One. 2013 Nov 08;8(11):e79748
pubmed: 24255713
Phytochem Rev. 2014;13:183-189
pubmed: 24578676
In Vitro Cell Dev Biol Anim. 2014 Oct;50(9):840-50
pubmed: 24938356
Mol Nutr Food Res. 2015 Jul;59(7):1274-91
pubmed: 25693744
J Hepatol. 2015 Sep;63(3):661-9
pubmed: 25937435
Int J Nanomedicine. 2015 Aug 05;10:5059-80
pubmed: 26345201
PLoS One. 2015 Sep 18;10(9):e0138754
pubmed: 26382065
Cell Div. 2015 Oct 12;10:6
pubmed: 26464579
Nutr Cancer. 2016;68(1):77-85
pubmed: 26771294
Oncology. 2016;90(2):69-78
pubmed: 26771576
Mol Med Rep. 2016 May;13(5):3763-70
pubmed: 27035875
Cell Biochem Biophys. 2015 Dec;73(3):681-6
pubmed: 27259310
Anticancer Res. 2016 Jul;36(7):3363-72
pubmed: 27354595
Cancer Treat Rev. 2016 Sep;49:37-44
pubmed: 27453294
Biomed Pharmacother. 2016 Dec;84:177-184
pubmed: 27657825
Onco Targets Ther. 2016 Sep 23;9:5825-5837
pubmed: 27713636
Cancer Chemother Pharmacol. 2016 Dec;78(6):1151-1161
pubmed: 27787644
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Med Sci Monit. 2017 Jan 12;23:163-171
pubmed: 28077837
Oncol Lett. 2016 Dec;12(6):4999-5006
pubmed: 28105206
Oncotarget. 2017 May 23;8(21):34405-34422
pubmed: 28159921
J Cancer Res Clin Oncol. 2017 Jul;143(7):1143-1154
pubmed: 28265769
J Exp Pharmacol. 2017 Mar 31;9:31-45
pubmed: 28435333
J Cancer. 2017 May 11;8(7):1271-1283
pubmed: 28607603
Curr Pharm Des. 2018;24(2):123-129
pubmed: 29141538
J Cell Physiol. 2018 Sep;233(9):6337-6345
pubmed: 29219177
Theranostics. 2018 Jan 1;8(3):723-734
pubmed: 29344301
Eur J Pharmacol. 2018 May 5;826:24-30
pubmed: 29501864
Int J Oncol. 2018 Aug;53(2):515-526
pubmed: 29901071
Life Sci. 2018 Sep 15;209:43-51
pubmed: 30056019
In Vitro Cell Dev Biol Anim. 2018 Oct;54(9):629-639
pubmed: 30136034
Bioimpacts. 2018;8(3):185-194
pubmed: 30211078
Urology. 1998 Feb;51(2):203-5
pubmed: 9495698